DRTS Company Profile and Key Details

Alpha Tau Medical Ltd (NASDAQ:DRTS) closed at $14.44 USD, gaining $0.17 (1.19%) from the previous close of $14.27. The stock is currently within 5% of its 52-week high $3.43 and $15.17. With a market capitalization of about $1.30 billion, Alpha Tau Medical Ltd is classified as a small-cap and shows market-like volatility (beta ~1.21). Key stats such as the average daily volume over the past year has been around 685.62 thousand shares, volume is running light vs its 52-week average. Headquartered in Jerusalem, JM, Alpha Tau Medical Ltd operates in the Healthcare sector and the Biotechnology industry. Led by CEO Uzi Sofer, the company employs approximately 121 people and listed since March 08, 2021. Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.

Short-term trend indicators are bearishly aligned (SMA20 7.62%, SMA50 20.77%, SMA200 85.07%). The stock’s 14-day RSI is 59.61 (neutral), while the ATR of 0.54 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.79% below its high and over 244.78% above its low. Average 10-day trading volume of 520.57 thousand shares is below the 3-month average of 677.89 thousand, indicating normal recent market interest.

Alpha Tau Medical Ltd last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.03. This means the shares are trading above this model’s fair value.

Alpha Tau Medical Ltd has 92.48 million shares outstanding. The public float is 64.10 million shares, elevated short interest at 5.17% of float. This equals 3.21 million shares. The short ratio is 4.01 days. Institutional investors hold 7.12% of the float. Insiders own 31.23%. Over the past six months, insider transactions show net selling. They sold 96.15 thousand shares across 9 transactions.

Alpha Tau Medical Ltd generated EPS of -$0.52 over the past year. Five-year average earnings growth is -19.9%. Wall Street analysts project EPS growth of 6.65% annually over the next five years. The latest quarter delivered EPS of -$0.50. The next quarter is forecast at -$0.12. Next year's EPS is expected at -$30.65. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 13 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $5.00. The high target offers 17.73% upside. The low target suggests -65.37% downside. The mean target is $12.24. This offers -15.24% upside. Alpha Tau Medical Ltd earnings surprise history is a mixed track record. The quarter that ended August 10, 2026, missed forecasts by 254.91%. The prior quarter beat by -7.69%. Over the last six quarters, Apple has recorded several small beats. These include -14.29% in May 19, 2025.

Alpha Tau Medical Ltd trades at a P/E ratio of -13.93, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 29.92 reflecting a rich premium to book value. The P/FCF stands at -39.96, also below market averages. Compared to sector medians, Alpha Tau Medical Ltd P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Alpha Tau Medical Ltd (NASDAQ:DRTS) shares are up 30.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Alpha Tau Medical Ltd trading at a premium to the broader market with a P/E of -13.93. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.44, suggesting -20.78% downside. Our AI forecast model points to short-term strength (3.74% over two weeks), a medium-term rise (10.73% over three months), and a longer-term gain (141.9% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Alpha Tau Medical Ltd stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.74%, with price expected at $14.98 by September 24, 2026, within a range of $14.33 to $15.62 3-Month Outlook: Projected rise of 10.73%, reaching $15.99 by December 09, 2026, with a range of $15.84 to $16.16. 1-Year Outlook: Projected gain of 141.9%, with price at $34.93 by September 10, 2027, within a range of $35.19 to $35.46.